MaaT Pharma Faces Regulatory Setback for Xervyteg® in aGvHD Treatment
Event summary
- MaaT Pharma received a 'negative trend' opinion from the EMA's CHMP on its conditional Marketing Authorization Application for MaaT013 (Xervyteg®) in treating acute Graft-versus-Host Disease (aGvHD).
- The CHMP formal vote is expected in June 2026, with MaaT Pharma planning to request a re-examination if the vote is unfavorable.
- The company is extending its financial runway to November 2026 to cover regulatory milestones and the re-examination process.
- MaaT013 (Xervyteg®) is supported by data from the ARES study and an ongoing Early Access Program with over 300 patients treated globally since 2019.
The big picture
MaaT Pharma's setback highlights the challenges faced by first-in-class therapies relying on novel approaches and single-arm pivotal trials. The company's commitment to addressing the unmet medical need in aGvHD and its engagement with the hematology community will be crucial in overcoming this regulatory hurdle. The outcome will have implications for the broader adoption of microbiome-driven therapies in oncology.
What we're watching
- Regulatory Pathway
- Whether MaaT Pharma can successfully navigate the re-examination process and secure approval for Xervyteg®.
- Financial Stability
- The company's ability to manage its extended financial runway while advancing its pipeline.
- Competitive Landscape
- How the delay in approval may impact MaaT Pharma's market position against established treatments like ruxolitinib.
Related topics